Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.

摘要

The absolute and relative change metrics are not meaningfully better than RECIST in predicting OS.